+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

  • ID: 5229221
  • Report
  • December 2020
  • Region: Global
  • 146 pages
  • IMARC Group
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • CureVac AG
  • Gradalis Inc.
  • Ionis Pharmaceuticals Inc
  • Merck & Co. Inc.
  • Moderna Inc.
  • Silence Therapeutics Plc
  • MORE
The global RNA interference (RNAi) drug delivery market grew at a CAGR of around 7% during 2014-2019. Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, the publisher expects the global RNA interference (RNAi) drug delivery market to continue its moderate growth during the next five years.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global rna interference (rnai) drug delivery market report, along with forecasts for growth at the global, regional and country level from 2020-2025. Our report has categorized the market based on region, application and technology.

Breakup by Application:
  • Infectious Disease
  • Cardiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Urology
  • Metabolic Disorders
  • Others
Breakup by Technology:
  • Nanoparticle Drug Delivery
  • Pulmonary Drug Delivery
  • Nucleic Acid Drug Delivery
  • Aptamer Drug Delivery
Breakup by Region:
  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac AG, Dicerna Pharmaceuticals Inc., Gradalis Inc., Ionis Pharmaceuticals Inc, Merck & Co. Inc., Moderna Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Silence Therapeutics Plc and Sirnaomics Inc.

Key Questions Answered in This Report:
  • How has the global RNA interference (RNAi) drug delivery market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global RNA interference (RNAi) drug delivery market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the technology?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global RNA interference (RNAi) drug delivery market and who are the key players?
  • What is the degree of competition in the industry?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • CureVac AG
  • Gradalis Inc.
  • Ionis Pharmaceuticals Inc
  • Merck & Co. Inc.
  • Moderna Inc.
  • Silence Therapeutics Plc
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global RNA Interference (RNAi) Drug Delivery Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Application
6.1 Infectious Disease
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Cardiology
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Oncology
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Neurology
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Ophthalmology
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Urology
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Metabolic Disorders
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Others
6.8.1 Market Trends
6.8.2 Market Forecast

7 Market Breakup by Technology
7.1 Nanoparticle Drug Delivery
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Pulmonary Drug Delivery
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Nucleic Acid Drug Delivery
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Aptamer Drug Delivery
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast

8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast

9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Alnylam Pharmaceuticals Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Arrowhead Pharmaceuticals Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.3 CureVac AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.4 Dicerna Pharmaceuticals Inc.
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.5 Gradalis Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.6 Ionis Pharmaceuticals Inc
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Merck & Co. Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Moderna Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.10 Silence Therapeutics Plc
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.11 Sirnaomics Inc.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio

List of Figures
Figure 1: Global: RNA Interference (RNAi) Drug Delivery Market: Major Drivers and Challenges
Figure 2: Global: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Billion US$), 2014-2019
Figure 3: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Application (in %), 2019
Figure 4: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Technology (in %), 2019
Figure 5: Global: RNA Interference (RNAi) Drug Delivery Market: Breakup by Region (in %), 2019
Figure 6: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Billion US$), 2020-2025
Figure 7: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market: Sales Value (in Million US$), 2014 & 2019
Figure 8: Global: RNA Interference (RNAi) Drug Delivery (Infectious Disease) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 9: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 10: Global: RNA Interference (RNAi) Drug Delivery (Cardiology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 11: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 12: Global: RNA Interference (RNAi) Drug Delivery (Oncology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 13: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 14: Global: RNA Interference (RNAi) Drug Delivery (Neurology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 15: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 16: Global: RNA Interference (RNAi) Drug Delivery (Ophthalmology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 17: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market: Sales Value (in Million US$), 2014 & 2019
Figure 18: Global: RNA Interference (RNAi) Drug Delivery (Urology) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 19: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market: Sales Value (in Million US$), 2014 & 2019
Figure 20: Global: RNA Interference (RNAi) Drug Delivery (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 21: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market: Sales Value (in Million US$), 2014 & 2019
Figure 22: Global: RNA Interference (RNAi) Drug Delivery (Other Applications) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 23: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market: Sales Value (in Million US$), 2014 & 2019
Figure 24: Global: RNA Interference (RNAi) Drug Delivery (Nanoparticle Drug Delivery) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 25: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market: Sales Value (in Million US$), 2014 & 2019
Figure 26: Global: RNA Interference (RNAi) Drug Delivery (Pulmonary Drug Delivery) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 27: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market: Sales Value (in Million US$), 2014 & 2019
Figure 28: Global: RNA Interference (RNAi) Drug Delivery (Nucleic Acid Drug Delivery) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 29: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market: Sales Value (in Million US$), 2014 & 2019
Figure 30: Global: RNA Interference (RNAi) Drug Delivery (Aptamer Drug Delivery) Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 31: North America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 32: North America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 33: United States: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 34: United States: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 35: Canada: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 36: Canada: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 37: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 38: Asia Pacific: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 39: China: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 40: China: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 41: Japan: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 42: Japan: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 43: India: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 44: India: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 45: South Korea: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 46: South Korea: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 47: Australia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 48: Australia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 49: Indonesia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 50: Indonesia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 51: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 52: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 53: Europe: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 54: Europe: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 55: Germany: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 56: Germany: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 57: France: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 58: France: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 59: United Kingdom: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 60: United Kingdom: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 61: Italy: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 62: Italy: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 63: Spain: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 64: Spain: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 65: Russia: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 66: Russia: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 67: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 68: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 69: Latin America: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 70: Latin America: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 71: Brazil: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 72: Brazil: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 73: Mexico: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 74: Mexico: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 75: Others: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 76: Others: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 77: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market: Sales Value (in Million US$), 2014 & 2019
Figure 78: Middle East and Africa: RNA Interference (RNAi) Drug Delivery Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 79: Global: RNA Interference (RNAi) Drug Delivery Industry: SWOT Analysis
Figure 80: Global: RNA Interference (RNAi) Drug Delivery Industry: Value Chain Analysis
Figure 81: Global: RNA Interference (RNAi) Drug Delivery Industry: Porter’s Five Forces Analysis

List of Tables
Table 1: Global: RNA Interference (RNAi) Drug Delivery Market: Key Industry Highlights, 2019 and 2025
Table 2: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Application (in Million US$), 2020-2025
Table 3: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Technology (in Million US$), 2020-2025
Table 4: Global: RNA Interference (RNAi) Drug Delivery Market Forecast: Breakup by Region (in Million US$), 2020-2025
Table 5: Global: RNA Interference (RNAi) Drug Delivery Market Structure
Table 6: Global: RNA Interference (RNAi) Drug Delivery Market: Key Players
Note: Product cover images may vary from those shown
3 of 4
  • Alnylam Pharmaceuticals Inc.
  • Arrowhead Pharmaceuticals Inc.
  • CureVac AG
  • Dicerna Pharmaceuticals Inc.
  • Gradalis Inc.
  • Ionis Pharmaceuticals Inc
  • Merck & Co. Inc.
  • Moderna Inc.
  • Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
  • Silence Therapeutics Plc
  • Sirnaomics Inc
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll